BioCryst Pharmaceuticals, Inc. announced that on January 4, 2013, Robert S. Lowrey, the Controller and Principal Accounting Officer tendered his resignation from employment with the company, effective January 25, 2013. Beginning January 26, 2013, Mr. Thomas Staab, who has been the company's Chief Financial Officer since July 1, 2011, will serve as the company's Chief Financial and Principal Accounting Officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.575 USD | -0.72% |
|
+17.49% | +27.30% |
Jul. 09 | BioCryst Pharmaceuticals Says Orladeyo Approved in Peru | MT |
Jul. 03 | Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.30% | 1.57B | |
+19.53% | 126B | |
+24.76% | 118B | |
+24.43% | 27.87B | |
-17.15% | 20.95B | |
-14.80% | 16.92B | |
-13.72% | 16.18B | |
+10.50% | 14.84B | |
-47.10% | 14.79B | |
+53.47% | 14.08B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Announces Executive Changes